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Resistance of vivax malaria to treatment with antifolates,
such as pyrimethamine (Pyr), is spreading as mutations in
the dihydrofolatereductase (dhfr) genes are selected and
disseminated. We tested the antitumor drug methotrexate
(MTX), a potent competitive inhibitor of dhfr, against 11
Plasmodium vivax isolates ex vivo, 10 of which had multiple
dhfr mutations associated with Pyr resistance. Despite
high-grade resistance to Pyr (median 50% inhibitory
concentration [IC50], 13,345 nM), these parasites were all
highly susceptible to MTX (median IC50, 2.6 nM). Given its
potency against Pyr-resistant P. vivax, the antimalarial
potential of MTX deserves further investigation.
In the early 1970s, 7 patients were successfully and safely treated
for Plasmodium vivax with low doses of methotrexate (MTX)
[1]. MTX, a potent antifolate, had then long been used to treat
leukemia and severe psoriasis. However, these observations were
not followed further. First, they coincided with reports of MTX
hepatotoxicity in persons ingesting low doses (2.5 mg/kg) over
prolonged periods (3 months to 6 years) [2], making the use of
MTX for malaria prophylaxis or for repeated treatment of en-
demic residents untenable. Second, MTX offered no obvious
advantages over other antifolates such as pyrimethamine (Pyr),
which were then used effectively against malaria. Forty years on,
widespread use of Pyr to treat malaria (principally in combi-
nation with sulphadoxine) has led to the selection and global
dissemination of antifolate resistance, not only for P. falciparum
but also for Plasmodium vivax [3–4]. Resistance to Pyr in
P. falciparum and P. vivax is conferred by one or more muta-
tions inthedihydrofolatereductase gene(dhfr)[ 5 ] .I n t e r e s t i n g l y ,
it was reported that MTX remains active against laboratory lines
of Pyr-resistant P. falciparum that carry multiple dhfr mutations
[6]. We wished to determine whether Pyr-resistant P. vivax
isolates were also susceptible to MTX. Secondarily, we wished to
investigatethe effectofmultiple mutationsinanotherimportant
antifolate resistance gene: P. vivax dihydropteroate synthase
(dhps)o nP. vivax MTX sensitivity.
METHODS
Isolate Collection and Culture
Twenty P. vivax isolates were collected from May to June 2009
from malaria patients attending the Shoklo Malaria Research
Unit (SMRU) clinics, Mae Sot region of Tak Province in
northwestern Thailand. These samples were collected from pa-
tients with no prior antimalarial therapy and with microscopi-
cally conﬁrmed P. vivax (parasitemia range 3,000–10,000
parasites/lL). After written consent, blood samples were col-
lected by venipuncture in 5-ml-volume lithium heparinized
tubes, which were transported to the laboratory at SMRU within
5 hours of collection. In 14 isolates, the majority (.80%) of the
parasites were at the mid-trophozoite stage (20 h after in-
vasion), and no schizonts were detected. These isolates were
chosen for drug susceptibility testing. After platelets and leu-
kocytes removal, the susceptibility of these P. vivax isolates to
MXT (Methotrexate hydrate MW 454.4; Sigma-Aldrich) or
Pyr (Pyrimethamine Vetranal MW248.7; Sigma-Aldrich) was
assessed as described elsewhere [7], with one important
change. Folate-reduced media based on McCoy’s 5A (Biowest)
were used: folic acid 0.01mg/mL and p-amino benzoic acid
0.0005 mg/L, as opposed to the regular McCoy’s 5A medium
(Gibco) of 10 mg/L and 1 mg/L, respectively. To determine the
effect of reduced-folate media on P. vivax growth and sensitivity
to drugs, assays on the ﬁrst 6 isolates were carried out in parallel
using one or the other of McCoy’s 5A media types (Figure 1).
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performed with the folic acid–reduced media.
Analysis
Dose response curves and 50% inhibitory concentration (IC50)
valueswerecalculated by ﬁtting thedata to a sigmoidal inhibitory
E-max pharmacodynamic model using Winnonlin version 4.1
(Pharsight). Eleven of the 14 drug response curves were suc-
cessfully modeled according to criteria published earlier [7]. The
median IC50 values presented in Figure 1 were compared using
a Wilcoxon matched-pairs test. Statistical analysis and graphics
were carried out using GraphPad Prism 5 software (version 5).
Genotyping
In addition to conﬁrmation of the parasite species by poly-
merase chain reaction [8], mutations present in the P. vivax dhfr
and dhps genes (Pvdhfr and Pvdhps) for all the isolates were
sought by ampliﬁcation of the relevant fragments followed by
DNA sequencing, as previously described [9].
Ethical Approval
The clinicalsamples examinedin this study were collectedunder
the following ethical guidelines in the approved protocols:
OXTREC 027-025 (University of Oxford, Centre for Clinical
Vaccinology and Tropical Medicine, United Kingdom) and
MUTM 2008-215 from the Ethics Committee of the Faculty of
Tropical Medicine, Mahidol University, Bangkok.
RESULTS AND DISCUSSION
Of the 11 Thai P. vivax isolates, 10 were successfully geno-
typed for mutations in residues of Pvdhfr and Pvdhps asso-
ciated with antifolate resistance (Table 1). Nine had quintuple
mutations in Pvdhfr (residues F57I, S58R, T61M, S117T,
D156N), and one had quadruple mutations. All carried a tri-
ple mutation in Pvdhps (residues A383G, K512M, A553G),
and in 4 isolates an additional mutation S382A was detected.
Ex vivo drug assays showed that all 11 isolates were highly
resistant to inhibition by Pyr, with median IC50 5 13,345 nM
(7036–15,287 nM [Table 1]), as predicted by the numerous
mutations in Pvdhfr. By contrast, the 11 Pyr-resistant P. vivax
isolated were highly susceptibility to MTX, with median
IC50 5 2.6 nM(2.2–2.9 nM). Unsurprisingly, the presence of
triple or quadruple mutations in Pvdhps did not affect the
sensitivity of P. vivax to MTX.
Figure 1. A, The effect of folic acid concentration in the growth media (McCoy's 5A), .01 mg/L (open symbols)vs. 10.0 mg/L (solid symbols), on the
ex vivo susceptibility of 6 paired Thai Plasmodium vivax isolates to pyrimethamine and methotrexate (MTX). B, Photomicrographs of Giemsa-stained
P. vivax thin films from a single isolate and grown in the presence of 10 nM MTX for 42h either in McCoy's medium with normal, 10.0 mg/L (upper panel),
or reduced, .01 mg/L (lower panel), concentrations of folic acid. At the higher folic acid concentration, P. vivax was protected from an otherwise inhibitory
effect of MTX (lower panel), as demonstrated by observation of numerous asexual stages that developed into mature schizonts(upper panel).
208 d JID 2011:203 (15 January) d Imwong et al.The ex vivo assays used in this study were conducted using
media with physiological folic acid levels (folic acid .01mg/ml).
This contrasts with many studies where folate-enriched media
(folic acid 10 mg/ml) were used, because it was thought that
high levels of folic acid were needed to obtain the levels of
P. vivax ex vivo maturation, which is necessary for meaningful
dose response modeling [7]. In this study we used 6 of the
isolates to establish that P. vivax maturation occurs efﬁciently
in folate-depleted media and that under these conditions
the IC50’s were 5- to 10-fold lower (Figure 1) than those ob-
tained in parallel using folate-enriched media (1,000-fold more
folate). These observations underline the importance of using
folic acid–reduced media to conduct antifolate sensitivity
testing.
Whereas it is clear that high doses of MTX (130–300 mg kg
-
1) taken over several weeks (with serum concentrations
often .1,000 lM) to treat neoplastic disorders are associated
with life-threatening adverse events [10], the lower doses of
methotrexate (0.1–0.4 mg kg
-1 in children and 7.5–30 mg kg
-1
per adult) given once weekly for the management of rheu-
matoid arthritis, psoriasis, and juvenile idiopathic arthritis
(including infants ,one year old) have limited side effects
[11–13]. Pharmacokinetic studies indicate that a daily dose of
5 mg in adults (0.05 mg kg
-1) results in serum MTX concen-
trations between 250 and 500 nM [13]. These levels are
sufﬁcient to fully inhibit P. vivax (this study) and P. falciparum
[14]. Thus, we propose that at low doses MTX or novel drugs
with similar structures may have utility for the short-term
treatment of malaria in children and in adults. Studies to ex-
plore the potential of MTX as an anti–P. falciparum agent
(clinicaltrial.gov, NCT00791531) are underway, and it is hoped
that similar investigations will eventually be conducted against
P. vivax.
It should be noted that MTX-resistant P. falciparum could be
relatively easily selected in culture [6], though the molecular
basis of this resistance is yet to be determined. Therefore, it is
important to ensure that any deployment of MTX for malaria
treatment is done in the context of combination therapies. The
P. vivax isolates that we collected in Thailand were more sen-
sitive to MTX than to artesunate [15], a drug increasingly used
in combination with piperaquine to treat chloroquine-resistant
vivax malaria as second-line treatment. Further studies are
needed to establish whether the pharmacokinetic properties of
MTX make it an adequate partner to artemisinins. It would also
be of interest to examine the potential synergy in a combination
of methotrexate with a dhfr inhibitor (such as WR99210), which
might be expected to reduce even further the in vivo concen-
tration of methotrexate required. We suggest that in vivo studies
are warranted to explore the potential of low doses of MTX in
the treatment of P. vivax.
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Table 1. The ex vivo sensitivity of 11 Thai Plasmodium vivax isolates to methotrexate (MTX) and pyrimethamine (Pyr) relative to
mutations in dhps and dhfr
Isolate Species
a
Plasmodium vivax gene locus Antimalarial
Pvdhps
b Pvdhfr
b Average IC50nM
S382A A383G K512M A553G V585 F57I S58R T61M S117T D156N Pyr MTX
WPP 5759 Pv A G M G V IRM T N 7,036 2.4
WPP 3839 Pv A G K G V IRM T N15,287 2.8
WPP 3443 Pv S1AG K G V IRM T N13,996 2.6
WPP 6225 Pv* S1AG K G V IRM T N14,837 2.6
WPP 3597 Pv S G K G V IRT TN 10,691 2.2
WPP 4206 Pv S G K G V IRM T N12,412 2.6
WPP 4767 Pv S G K G V IRM T N12,259 2.9
WPP 3649 Pv S G K G V IRM T N13,345 2.2
WPP 6100 Pv S G K G V IRM T N14,085 2.6
WPP 6385 Pv* S G K G V IRM T N13,220 2.2
WPP 3559 Pv S G K G V ND ND ND ND ND 15,287 2.6
NOTE. The mutant amino acid at each of the residues is boldface and italicized. ND 5 Not determined.
a The presence of P. vivax (Pv) was conﬁrmed by polymerase chain reaction; in 2 cases submicroscopic P. falciparum (*) was noted.
b The position of the mutated residue is indicated, and the amino acid resulting from mutation is presented in boldface and italics.
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